Dr. Daniel Judge and Dr. C. Michael Gibson: Acoramidis from bench to bedside November 12, 2023 Disclosures: TBD
Dr. Steven Nissen and Dr. C. Michael Gibson Discuss: Efficacy and Safety of Lepodisiran: An Extended Duration Short-Interfering RNA Targeting Lipoprotein (a) November 12, 2023 Disclosures: TBD
Dr. Andrew Bellinger, Dr. Sek Kathiresan and Dr. C. Michael Gibson Discuss: Safety and Pharmacodynamic Effects of VERVE-101, an Investigational DNA Base Editing Medicine Designed to Durably Inactivate the PCSK9 Gene and Lower LDL Cholesterol – Interim Results of the Phase 1b heart-1 Trial November 12, 2023 Disclosures: TBD
Dr. Nina Becher and Dr. C. Michael Gibson Discuss: Efficacy and Safety of Anticoagulation With Edoxaban in Patients With AHRE Durations ≥24 Hours. The NOAH-AFNET 6 Trial November 12, 2023 Disclosures: TBD
Dr. Christian T Ruff and Dr. C. Michael Gibson Discuss: Abelacimab, a Novel Factor XI/XIa Inhibitor, vs Rivaroxaban in Patients with Atrial Fibrillation: Primary Results of the AZALEA-TIMI 71 Randomized Trial November 12, 2023 Disclosures: TBD
Dr. George Bakris and Dr. C. Michael Gibson Discuss: Sustained Blood Pressure Reduction With the RNA Interference Therapeutic Zilebesiran: Primary Results From KARDIA-1, a Phase 2 Study in Patients With Hypertension November 11, 2023 Disclosures: TBD
Dr. Mandeep Mehra and Dr. C. Michael Gibson Discuss: Avoidance of Aspirin With Left Ventricular Assist Devices in Advanced Heart Failure: Primary Results of the International, Double-Blind, Placebo-Controlled ARIES HM3 Clinical Trial November 11, 2023 Disclosures: TBD
Dr. Christopher Rajkumar, Dr. Rasha Al-Lamee and Dr. C. Michael Gibson Discuss: Percutaneous Coronary Intervention for Stable Angina (ORBITA-2): A Randomised, Placebo-Controlled Trial November 11, 2023 Disclosures: TBD
Dr. Jeffrey Carson and Dr. Serge Korjian Discuss: Restrictive versus Liberal Blood Transfusion in Patients With Myocardial Infarction and Anemia: Results of the MINT Trial November 11, 2023 Disclosures: TBD
Dr. Stefan K. James Presents: DAPA-MI – A Registry-Based Randomized Trial of Dapagliflozin in Patients With Acute Myocardial Infarction Without Diabetes November 11, 2023 Disclosures: TBD
